rct
    2017
    High Quality

    Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

    Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S

    Published in New England Journal of Medicine

    Key Findings

    Cannabidiol reduced median convulsive seizure frequency from 12.4 to 5.9 per month versus 14.9 to 14.1 with placebo.

    Conclusions

    Pharmaceutical-grade cannabidiol is effective add-on therapy in Dravet syndrome.

    Limitations

    Specific syndrome, high rate of adverse events and drug interactions.

    Related Health Concerns

    Epilepsy

    Study Details

    Year:2017
    Sample Size:120
    Duration:14 weeks
    Quality Score:9/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.